ArticleMolecular and clinical oncology2025
Liver metastasis surgery followed by radical treatment for pancreatic ductal adenocarcinoma: A case report.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) with liver metastasis is poor; therefore, chemotherapy is often selected instead of surgical intervention. However, there are some reports of cases becoming resectable after multidisciplinary treatment. On the other hand, there have been a few cases of long-term survival in which liver metastases were resected first, followed by prolonged chemotherapy and subsequent resection of the primary tumor. The present study describes the case of a patient with PDAC in which a liver metastasis was resected first, followed by chemotherapy and subsequent resection of the primary tumor, resulting in long-term survival. Briefly, a 72-year-old man diagnosed with resectable PDAC was scheduled to undergo subtotal stomach-preserving pancreaticoduodenectomy after neoadjuvant chemotherapy. Intraoperatively, a liver metastasis was detected, and partial hepatectomy was performed. The patient received 13 cycles of modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. A subtotal stomach-preserving pancreaticoduodenectomy was then performed when no new lesions were observed. The patient received S-1 as adjuvant chemotherapy for 1 year postoperatively. Currently, 5 years after diagnosis, and 4 years and 3 months after the last surgery, the patient has experienced no recurrence. In conclusion, even if curative surgery is not possible because of a liver metastasis at the time of the initial operation, some patients may achieve long-term survival through resection, and preoperative and postoperative chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.